Holen Sie sich die Stockscreener-App
4.035
1.13%
0.045
Handel nachbörslich:
4.04
0.005
+0.12%
Schlusskurs vom Vortag:
$3.99
Offen:
$4.04
24-Stunden-Volumen:
58,661
Relative Volume:
0.65
Marktkapitalisierung:
$111.65M
Einnahmen:
$21.25M
Nettoeinkommen (Verlust:
$-16.05M
KGV:
-4.035
EPS:
-1
Netto-Cashflow:
$-17.14M
1W Leistung:
-5.28%
1M Leistung:
-11.12%
6M Leistung:
-42.68%
1J Leistung:
-51.50%
1-Tages-Spanne:
$3.96
$4.11
1-Wochen-Bereich:
$3.96
$4.565
52-Wochen-Spanne:
$3.96
$11.92
Fennec Pharmaceuticals Inc Stock (FENC) Company Profile
Firmenname
Fennec Pharmaceuticals Inc
Sektor
Branche
Telefon
(919) 636-4530
Adresse
PO BOX 13628, RESEARCH TRIANGLE PARK, NC
Vergleichen Sie FENC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| FENC | 4.035 | 111.65M | 21.25M | -16.05M | -17.14M | -1.00 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Fennec Pharmaceuticals Inc Stock (FENC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-11-22 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2022-09-07 | Eingeleitet | CapitalOne | Overweight |
| 2022-08-08 | Fortgesetzt | Craig Hallum | Buy |
| 2020-06-05 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-10-11 | Eingeleitet | Goldman | Buy |
Fennec Pharmaceuticals Inc Aktie (FENC) Neueste Nachrichten
DG Capital Management, LLC Adjusts Stake in Fennec Pharmaceutica - GuruFocus.com
Fennec Pharmaceuticals to Participate in Upcoming Investor Conference - The Manila Times
Fennec Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2024 - Marketscreener.com
Fennec Pharmaceuticals Drops To US$4.26, Yet Insiders May Have Sold Too Early - Simply Wall St
Fennec Pharmaceuticals Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance
Fennec Pharma stock hits 52-week low at $4.07 amid challenges - Investing.com India
Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Q3 2024 Earnings Call Transcript - Insider Monkey
Wedbush Analysts Decrease Earnings Estimates for FENC - MarketBeat
What is Wedbush's Forecast for TSE:FRX FY2025 Earnings? - MarketBeat
Earnings call: Fennec Pharmaceuticals reports robust Q3 growth By Investing.com - Investing.com Australia
Earnings call: Fennec Pharmaceuticals reports robust Q3 growth - Investing.com
Wedbush Reaffirms “Outperform” Rating for Fennec Pharmaceuticals (NASDAQ:FENC) - Defense World
Fennec Pharmaceuticals Inc (FENC) Quarterly 10-Q Report - Quartzy
Fennec Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times
Fennec Pharma Q3 Sales Rise to $7M, Losses Widen Despite PEDMARK Reimbursement Success | FENC Stock News - StockTitan
Apogee Therapeutics (NASDAQ:APGE) and Fennec Pharmaceuticals (NASDAQ:FENC) Financial Contrast - Defense World
FENCFennec Pharmaceuticals Inc. Latest Stock News & Market Updates - StockTitan
Insider Sale: Director Rosty Raykov Sells Shares of Fennec Pharm - GuruFocus.com
Insider Selling: Fennec Pharmaceuticals Inc (NASDAQ:FENC) Director Sells 2,431 Shares of Stock - MarketBeat
Fennec Pharmaceuticals director Raykov Rosty sells $10,477 in stock - Investing.com India
Fennec Pharmaceuticals director Raykov Rosty sells $10,477 in stock By Investing.com - Investing.com South Africa
Fennec Pharmaceuticals (FENC) to Release Earnings on Thursday - MarketBeat
Fennec Pharmaceuticals (FRX) Set to Announce Quarterly Earnings on Thursday - MarketBeat
Fennec Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024 - ForexTV.com
RTP drugmaker appoints new execs following CEO swap - The Business Journals
Fennec Pharmaceuticals Strengthens Leadership Team for Growth - TipRanks
Individual investors account for 31% of Fennec Pharmaceuticals Inc.'s (NASDAQ:FENC) ownership, while hedge funds account for 30% - Yahoo Finance
Fennec Pharmaceuticals (TSE:FRX) Stock Price Passes Below 50 Day Moving AverageWhat's Next? - MarketBeat
Eupraxia Pharmaceuticals Inc. - Baystreet.ca
Fennec Pharmaceuticals expands leadership team - The Pharma Letter
Fennec Pharmaceuticals Inc. - Baystreet.ca
Fennec Pharmaceuticals Strengthens Executive Leadership Team with Three Key Appointments to Accelerate the Company's Next Stage of Growth - The Manila Times
Fennec Pharmaceuticals Strengthens Executive Leadership Team with Three Key Appointments to Accelerate the Company’s Next Stage of Growth - ForexTV.com
Q3 EPS Estimates for FENC Boosted by Capital One Financial - Defense World
Capital One Financial Estimates TSE:FRX Q3 Earnings - MarketBeat
Financial Comparison: Kodiak Sciences (NASDAQ:KOD) & Fennec Pharmaceuticals (NASDAQ:FENC) - Defense World
Fennec Pharma stock hits 52-week low at $4.11 amid market challenges - Investing.com India
Fennec Pharmaceuticals director sells shares worth over $6,000 By Investing.com - Investing.com South Africa
Fennec Pharma stock hits 52-week low at $4.11 amid market challenges By Investing.com - Investing.com South Africa
Fennec Pharmaceuticals director sells shares worth over $6,000 - Investing.com
Fennec Pharmaceuticals (TSE:FRX) Reaches New 12-Month LowTime to Sell? - MarketBeat
Fennec: Operational Challenges Persist Despite Improved Financial Position (NASDAQ:FENC) - Seeking Alpha
Rostislav Christov Raykov Sells 2,431 Shares of Fennec Pharmaceuticals Inc. (TSE:FRX) Stock - Defense World
Revenues Working Against Fennec Pharmaceuticals Inc.'s (NASDAQ:FENC) Share Price - Simply Wall St
Fennec Pharma stock hits 52-week low at $4.57 amid market challenges - Investing.com
Fennec Pharmaceuticals director sells over $12k in company stock - Investing.com India
Norgine Announces Appointment of New CEO Janneke van der Kamp - PR Newswire UK
Fennec Pharmaceuticals Inc (NASDAQ:FENC) Director Sells $12,009.14 in Stock - Defense World
The past three years for Fennec Pharmaceuticals (NASDAQ:FENC) investors has not been profitable - Yahoo Finance
Finanzdaten der Fennec Pharmaceuticals Inc-Aktie (FENC)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):